This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Corrine K. Hanson, PhD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT01469650
First received: November 8, 2011
Last updated: September 13, 2017
Last verified: September 2017
  Purpose
The specific aims of this study are to determine levels of vitamin D supplementation to achieve goal serum 25(OH)D levels of 30 ng/mL, and to define serum 25(OH)D levels required to achieve suppression of parathyroid hormone in preterm newborn infants hospitalized in the Nebraska Medical Center Newborn Intensive Care Nursery (NICU). In this randomized, controlled trial, infants 23 weeks gestational age or greater will be randomized to two different levels of vitamin D supplementation: 400 IU vitamin D3/day, or 800 IU vitamin D3/day. As an exploratory aim, vitamin D binding protein levels (VDBP) will also be quantified in these infants.

Condition Intervention
Premature Infants Dietary Supplement: cholecalciferal Dietary Supplement: cholecalciferol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants

Resource links provided by NLM:


Further study details as provided by Corrine K. Hanson, PhD, University of Nebraska:

Primary Outcome Measures:
  • Serum 25(OH)D Levels [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Parathyroid Hormone Levels [ Time Frame: 1 year ]

Enrollment: 32
Actual Study Start Date: January 2012
Study Completion Date: July 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 400 IU/day vitamin D
Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
Dietary Supplement: cholecalciferal
400 IU/day
Other Name: vitamin D3
Experimental: 800 IU/day vitamin D3
Subjects will receive 800 IU/day vitamin D3
Dietary Supplement: cholecalciferol
800 IU/day D3
Other Name: vitamin D3

  Eligibility

Ages Eligible for Study:   23 Weeks to 32 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • NICU hospitalized infants
  • 23-32 weeks gestation

Exclusion Criteria:

  • congential anomalies
  • disorders of calcium metabolism
  • inborn error of metabolism
  • kidney disease
  • liver disease
  • use of steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01469650

Locations
United States, Nebraska
Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
  More Information

Responsible Party: Corrine K. Hanson, PhD, Assistant Professor, University of Nebraska
ClinicalTrials.gov Identifier: NCT01469650     History of Changes
Other Study ID Numbers: 419-11-FB
Study First Received: November 8, 2011
Last Updated: September 13, 2017

Keywords provided by Corrine K. Hanson, PhD, University of Nebraska:
vitamin D3
prematurity
parathyroid hormone
25(OH)D
NICU hospitalization

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Hormones
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on September 19, 2017